155 related articles for article (PubMed ID: 36089724)
41. Incomplete Intestinal Obstruction Caused by a Rare Epithelioid Inflammatory Myofibroblastic Sarcoma of the Colon: A Case Report.
Bai Y; Jiang M; Liang W; Chen F
Medicine (Baltimore); 2015 Dec; 94(51):e2342. PubMed ID: 26705227
[TBL] [Abstract][Full Text] [Related]
42. Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.
Chopra S; Maloney N; Wang WL
Brain Tumor Pathol; 2022 Jan; 39(1):35-42. PubMed ID: 34743247
[TBL] [Abstract][Full Text] [Related]
43. Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.
Li X; Zheng J; Li X; Chen Y; Liu K; Li F; Lu Z
Front Oncol; 2023; 13():1252221. PubMed ID: 37869075
[TBL] [Abstract][Full Text] [Related]
44. [A leukemoid leucocytosis].
Cherif E; Kechaou I; Hassine LB; Boukhris I; Azzabi S; Kaouech Z; Kooli C; Khalfallah N
Ann Biol Clin (Paris); 2012; 70(3):333-4. PubMed ID: 22565182
[TBL] [Abstract][Full Text] [Related]
45. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
46. Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry, and molecular cytogenetic analysis.
Lee JC; Wu JM; Liau JY; Huang HY; Lo CY; Jan IS; Hornick JL; Qian X
Cancer Cytopathol; 2015 Aug; 123(8):495-504. PubMed ID: 26139079
[TBL] [Abstract][Full Text] [Related]
47. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
48. A Rare Case of Incidentally Diagnosed Pulmonary Inflammatory Myofibroblastic Tumour with Dramatic Response to Crizotinib in a Postpartum Woman.
Yorke J; Solanki K; Theegala V; Georges T; Sinha AK; Asberry DE; El Abbassi A
Eur J Case Rep Intern Med; 2023; 10(4):003626. PubMed ID: 37051474
[TBL] [Abstract][Full Text] [Related]
49. Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma.
Gouveia E; Sousa M; Passos MJ; Moreira A
BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25576527
[TBL] [Abstract][Full Text] [Related]
50. Inflammatory fibrous histiocytoma presenting leukemoid reaction.
Takahashi K; Kimura Y; Naito M; Yoshimura T; Uchida H; Araki S
Pathol Res Pract; 1989 May; 184(5):498-506. PubMed ID: 2546130
[TBL] [Abstract][Full Text] [Related]
51. Epithelioid inflammatory myofibroblastic sarcoma: the youngest case reported.
Batool S; Ahuja A; Chauhan DS; Bhardwaj M; Meena AK
Autops Case Rep; 2021; 11():e2021288. PubMed ID: 34249792
[TBL] [Abstract][Full Text] [Related]
52. Esophageal adenocarcinoma with leukemoid reaction: a case report.
Yu G; Ji H; Meng C; Huang Y; Gao G; Liu C; Wang S; Zhang L; Ju J
J Cardiothorac Surg; 2019 Apr; 14(1):66. PubMed ID: 30961609
[TBL] [Abstract][Full Text] [Related]
53. Pericardial Epithelioid Inflammatory Myofibroblastic Sarcoma: An Atypical Presentation.
Azad M; Oye M; Torrente N; Mirsaeidi M
Cureus; 2022 Jul; 14(7):e26827. PubMed ID: 35847167
[TBL] [Abstract][Full Text] [Related]
54. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
55. Leukemoid reaction in the pediatric population: etiologies, outcome, and implications.
Hoofien A; Yarden-Bilavski H; Ashkenazi S; Chodick G; Livni G
Eur J Pediatr; 2018 Jul; 177(7):1029-1036. PubMed ID: 29696475
[TBL] [Abstract][Full Text] [Related]
56. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
57. Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism.
Kurihara-Hosokawa K; Kawasaki I; Tamai A; Yoshida Y; Yakushiji Y; Ueno H; Fukumoto M; Fukushima H; Inoue T; Hosoi M
Intern Med; 2014; 53(19):2211-4. PubMed ID: 25274232
[TBL] [Abstract][Full Text] [Related]
58. Paraneoplastic leukemoid syndrome in squamous cell carcinoma of the forearm.
Das S; Shaikh OH; Prakash S; Gopal B
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36634990
[TBL] [Abstract][Full Text] [Related]
59. Paraneoplastic leukemoid reaction as marker for transitional cell carcinoma recurrence.
Dukes JW; Tierney LM
Urology; 2009 Apr; 73(4):928.e17-9. PubMed ID: 18718647
[TBL] [Abstract][Full Text] [Related]
60. Leukemoid reaction in malignant bone tumor patients - a retrospective, single-institution study.
Ma X; Li G; Cai Z; Sun W; Liu J; Zhang F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1895-9. PubMed ID: 23242713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
